The global genomics market is expected to reach USD 27.6 billion by 2025
The past decades have witnessed significant changes in disease management processes due to simultaneous advancements in genomics and personalized medicine. There has been a gradual growth in the usage of genomic studies in clinical practices, which is reflected by the growing trend of targeted therapies.
Results from genomic studies enable a better understanding of diseases and the underlying mechanisms for researchers, physicians, and consumers. This facilitates evidence-based decision-making, and hence, helps improve personalized treatment regime. In addition, technological advancements in data analysis tools have motivated healthcare community to create precision-based therapies from surplus, available DNA data.
Advancements in genomics and associated technologies has significantly impacted crop genetics. Technological advancements in sequencing facilitates genomes & transcriptomes sequencing for several crops. Although a reference genome exists for several crops, resequencing and gene expression studies are required for in-depth study of key genes contributing to the desired trait. Implementation of this information in crop breeding helps in development of advanced crops.
The companies are involved in strategic alliances with global as well as local entities to boost their revenue generation and enhance their share in the market. For instance, in March 2017, Foundation Medicine collaborated with Bristol-Myers Squibb Company, as a result of which Bristol-Myers Squibb could deploy Foundation Medicine's molecular information solutions and comprehensive genomic profiling for identification of predictive biomarkers, such as Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB), to accelerate its immunotherapy clinical trials. Such initiatives are aimed at increasing the adoption of genomic information in cancer management.
Further Key Findings From the Report Suggest:
High volume requirement and the high cost of specific reagents contribute to substantial revenue share. Companies are embracing the trend of offering varied reagents that simplify workflow process
NGS-based services held a major share in the genomics services segment due to its rapid adoption of whole genome sequencing and application of sequence databases for disease screening and prognosis
NGS-based services have witnessed a continuous growth since its introduction
The demand for these services would remain strong with the expansion of the customer base from being limited to academic and research centers to CROs, biotech and pharma players.
Biomarkers exhibit high clinical potential and efficiency across treatment of wide range of diseases
Use of predictive biomarkers for diagnosis and monitoring take cancer eradication a step further. Moreover, organizations and programs such as National Biomarker Development Alliance (NBDA) are actively participating in development of novel biomarkers for cancer diagnosis
Thus biomarkers are expected to exhibit the fastest growth in the coming years over the forecast period
The growing interest of pharmaceutical and biotechnology companies in genomics is expected to drive market growth in the coming years.
As patients are focusing on their health, Direct-To-Consumer (DTC) laboratory testing is increasingly being employed. DTC genetic tests enable consumers to access information about their genetics without necessarily including healthcare professionals in the process.
A few emerging and established companies are competing in this space
Asia Pacific is the most potential region and an emerging market for genomics. This market is anticipated to grow at the highest CAGR of 12.7%.
Developing infrastructure in these countries has led to the increased demand for biomarkers for diagnostics purposes.
Market participants are engaged in making the technology available to users at a lower price and in a compact form
Key Topics Covered:
Chapter 1 Executive Summary 1.1 Market Snapshot
Chapter 2 Research Methodology 2.1 Information Procurement 2.2 Information or Data Analysis 2.3 Market Formulation & Validation
Chapter 3 Genomics Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 126.96.36.199 Growing integration of genomics data into clinical workflows 188.8.131.52.1 More targeted and personalized healthcare 184.108.40.206.2 Growth of newborn genetic screening programs 220.127.116.11.3 Advancements in noninvasive cancer screening 18.104.22.168.4 Military genomics 22.214.171.124 Technological advances to facilitate genomic R&D 126.96.36.199.1 Emergence of advanced genome editing techniques 188.8.131.52.2 Integration of new data streams 184.108.40.206.3 RNA biology 220.127.116.11.4 Single cell biology 18.104.22.168 Rising adoption of direct to consumer genomics 22.214.171.124 Success of genetic tools in agrigenomics 126.96.36.199 Increasing participation of different companies 188.8.131.52 Increase in government role and funding in genomics 3.1.2 Market restraint analysis 184.108.40.206 Issues regarding intellectual property protection, data management, and public policies 220.127.116.11 Dearth of skilled personnel 3.2 Penetration & Growth Prospect Mapping for End use, 2016 3.3 Genomics - Swot Analysis, By Factor (Political & Legal, Economic And Technological) 3.4 Industry Analysis - Porter's
Chapter 5 Genomics Market Categorization: Technology - Application Estimates & Trend Analysis 5.1 Global Genomics Market: Technology - Application Movement Analysis 5.2 Functional Genomics 5.2.1 Global functional genomics market, 2014 - 2025 (USD Million) 5.2.2 Transfection 5.2.3 Real time PCR 5.2.4 RNA interference 5.2.5 Mutational analysis 5.2.6 SNP analysis 5.2.7 Microarray analysis 18.104.22.168 Global microarray analysis in functional genomics market, 2014 - 2025 (USD Million) 5.3 Epigenomics 5.3.1 Global epigenomics market, 2014 - 2025 (USD Million) 5.3.2 Bisulfite sequencing 5.3.3 Chromatin immunoprecipitation-sequencing (ChIP-Seq) 5.3.4 Methylated DNA immunoprecipitation (MeDIP) 5.3.5 High resolution melt 5.3.6 Chromatin accessibility assays 5.3.7 Microarray analysis 5.4 Pathway Analysis 5.4.1 Global pathway analysis market, 2014 - 2025 (USD Million) 5.4.2 Bead-based analysis (Bio-Plex) 5.4.3 Microarray analysis 5.4.4 Real time PCR 5.4.5 Proteomics tools (2-D PAGE; yeast 2-hybrid studies) 5.5 Biomarker Discovery 5.5.1 Global biomarker discovery market, 2014 - 2025 (USD Million) 5.5.2 Mass spectrometry 5.5.3 Real time PCR 5.5.4 Microarray analysis 5.5.5 Statistical analysis 5.5.6 Bioinformatics 5.5.7 DNA sequencing 5.6 Others 5.6.1 Global other services market, 2014 - 2025 (USD Million)
Chapter 6 Genomics Market Categorization: End-use Estimates & Trend Analysis 6.1 Genomics Market: End-use Movement Analysis 6.2 Clinical & Research Laboratories 6.3 Academic and Government Institutes 6.4 Hospitals and Clinics 6.5 Pharmaceutical and Biotechnology Companies 6.6 Other End Users